SC Filed 2019-05-28 Event — SEC 0001072613-19-000202 →

New Enterprise Associates 16, L.P. → X4 Pharmaceuticals, Inc XFOR

Stake: — Shares: —

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

4 13D/G filings on this issuer

3 other filings besides this one

Filer Track Record

10 filings by this filer

9 other filings in the data moat

Short Interest · settle 2026-07-15

DTC 9.79

6,501,966 shares short · +18.1% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $3.23M

Point72 Asset Mgmt

Other 13D/G Filings on X4 Pharmaceuticals, Inc

Filed	Form	Filer	Stake	Shares
2019-07-17	SC	Polaris Venture Partners V, L.P.	—	—	view →
2019-03-19	SC	ORBIMED ADVISORS LLC	—	—	view →
2018-01-26	SC	ORBIMED ADVISORS LLC	—	—	view →

Other Filings by New Enterprise Associates 16, L.P.

Filed	Form	Issuer	Stake	Shares
2025-08-18	SCHEDULE	Marker Therapeutics, Inc. MRKR	12.60%	1,625,678	view →
2025-08-11	SCHEDULE	Trevi Therapeutics, Inc. TRVI	12.00%	15,074,080	view →
2022-01-05	SC	Metacrine, Inc.	—	—	view →
2021-04-14	SC	GENOCEA BIOSCIENCES, INC.	—	—	view →
2021-03-26	SC	Marker Therapeutics, Inc. MRKR	—	—	view →
2021-03-11	SC	Allakos Inc.	—	—	view →
2020-08-03	SC	GENOCEA BIOSCIENCES, INC.	—	—	view →
2020-04-16	SC	Trevi Therapeutics, Inc. TRVI	—	—	view →
2019-02-22	SC	GENOCEA BIOSCIENCES, INC.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →